Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →We are pleased that AbbVie, a global leader in the development of novel therapeutics, has chosen Halozyme's ENHANZE platform to augment their development…
In the ENHANZE pillar, we signed our largest licensing agreement in company history with AbbVie, which has the potential to generate new royalty revenue and…
AbbVie discontinued its development program with Halozyme after a Phase 1 trial of the high-concentration Humira formulation fell short — a setback for a…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie and Halozyme entered a global collaboration applying Halozyme's ENHANZE platform to up to nine AbbVie targets. Halozyme received $23M upfront with up to $130M in milestones per target (~$1.17B aggregate across 9 targets). AbbVie terminated the collaboration November 2016.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Halozyme Therapeutics, Inc. (ENHANZE platform) (this deal) | 2015 | $1.2B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2015 deals · AbbVie Inc. deals · Multiple (undisclosed) deals